Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck CancerJulie E. Bauman, Laura P. Stabile, James Ohr et al.|Cancers|2020Cited by 30
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinomaSuet Kee Loo, Shou‐Jiang Gao, Gabriel Sica et al.|Cell & Bioscience|2024Cited by 3
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Julie E. Bauman, Laura P. Stabile, Umamaheswar Duvvuri et al.|Journal of Clinical Oncology|2017Cited by 2
Supplementary Data from Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor MigrationManjulata Singh, Shilpa Sant, Xiaojun Tian et al.|Unknown|2023Cited by 0
Supplementary Data from Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor MigrationManjulata Singh, Shilpa Sant, Xiaojun Tian et al.|Unknown|2023Cited by 0